You may know the price of site training, but what about the actual cost to your clinical trial?
Training site staff on the specifics of conducting a clinical trial takes time and money. But do you fully appreciate the cost and impact of inadequately trained staff to your clinical trial?
We’ve all experienced poor training: overly long sessions; pages of dense content or legalese with little or no learning impact; poorly designed e-Learning which is difficult to navigate, or the dreaded “death by PowerPoint” meetings. When we are not engaged, training is little more than a box-ticking exercise – it is possible to be technically trained without having achieved the learning objective.
In contrast, effective training using rich and varied content, leveraging highly engaging methodology will provide a positive user experience. Learners should feel confident in their understanding of the topic and this comprehension should be assessed and reinforced with an appropriate level of knowledge checks. The learner should walk away remembering key points and retain this knowledge long after the training session is completed.
Why is site training so important?
The clinical trial industry is a highly regulated environment with a primary focus on compliance to protocol and clinical standards, with the goal of delivering the highest quality data and protecting patient safety. Ensuring site staff receive adequate training, and that this is tracked on an ongoing basis throughout the clinical trial, is not only advisable but essential. It is also important that the tracking and reporting of training is transparent for audit purposes.
Failure to address this critical aspect could have impact of time, quality, and cost of your clinical trial.
- Lack of understanding in the details of the protocol - leading to misinterpretation of visit requirements with potential patient safety issues.
- According to Tufts protocols now have more endpoints than ever, according with the mean number of eligibility criteria across clinical trials in 2023 at 32.2.
- Deviations from the protocol could occur - leading to non-compliant data
- Errors in trial conduct could risk approval and could de-rail your clinical development programme.
- Lack of awareness of details in inclusion and exclusion criteria - resulting in longer patient recruitment timelines and delays in bringing the drug or device to market and overall increased cost of the trial.
- One of the most valuable results of good training is that site staff become much more conversant in the trial and comfortable talking about it to potential participants. According to Tufts Impact Report for January/February 2024, nearly half of sites in 2023 (47%) either under-enrolled (33%) of failed to enrol a patient (14%) in the trial – the figure has not changed since 2019.
- The same Tufts Impact Report noted that oncology and CNS/neuroscience trials had significantly higher mean numbers of eligibility criteria than vaccines and inflammatory trials making site training even more important to ensure the right patients are enrolled.
The impact of poor training, extends beyond compliance and has the potential to affect recruitment.
![blog-site training-Site enrollment graph- Tufts Jan-Feb 2024 blog-site training-Site enrollment graph- Tufts Jan-Feb 2024](https://icon.widen.net/content/lvhrs1azlr/original/blog-site-training-Site-enrollment-graph--Tufts-Jan-Feb-2024.png?u=z8skf3)
Considerations in choosing a comprehensive site training solution
- Choose a training solution that is fit for purpose: Training site staff is different from standard in-house business training on applications. The solution should be developed by a multi-disciplinary team of clinical trial specialists in collaboration with e-Learning, graphic design, and quality professionals. The clinical trial experts will understand the mindset of site staff and be able to understand and address issues facing clinical trial professionals on a daily basis.
- Make access easy: Site staff are busy, and their priority is looking after the patient. it’s important that the access you provide to staff is user friendly and role based to avoid difficult navigation and excessive scrolling.
- Ensure training is specific to the study: Proving non-necessary or general training will frustrate site staff. Make your training as specific to the study as possible. For example, study-specific protocol training designed to improve understanding of the protocol and improve study compliance and facilitate quality learning with self-paced, interactive lessons that optimises user engagement and learning retention through streamlined information, intuitive navigation, and a combination of 2D and 3D graphics.
- Provide just in time options to ensure staff are up to date as the trial progresses: Make it easier for site staff by providing visit by visit, detailed instructions on how to conduct study visits and conduct procedures in compliance with the protocol. It empowers sites in the study to execute study visits more consistently and accurately, thereby driving down deviations.
- Deliver training that supports staff to meet study timelines such as patient recruitment: For example, providing training on how to pre-screen patients will support site staff to ask the right questions and facilitates the identification of patients that may be potentially suitable for participation in a clinical trial.
- Support site staff to engage patients: Making patient education modules available to site staff will help them to relay key pieces of information relevant to their decision-making in participation and enhance patient retention.
- Ensure technology is compliant with regulatory21-CFR Part 11 compliant.
Contact us to today to find out more about what you need to put in place to reduce risk, increase compliance and enhance quality with a comprehensive training solution.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel